Regarding fluidic biomarkers, the analysis of amyloid-β peptide (Aβ42), tau, and phospho-tau (p-tau) in cerebrospinal fluid (CSF) has long been the gold standard for AD diagnosis [3]. Here, MAPT is linked to Alzheimer disease.